CSIMarket
 



Arbutus Biopharma Corp  (ABUS)
Other Ticker:  
 
 



 

What are Arbutus Biopharma's Business Segments?



Arbutus Biopharma Corp is a biotech company that focuses on the discovery, development and commercialization of cure for infectious diseases using RNA technologies. The company offers a wide range of segments, products and services to achieve this aim. These segments consist of:

1. Research and development segment: In this segment, Arbutus Biopharma Corp conducts various research and development activities to develop RNA-based therapies that can combat viral infections. The company has a team of scientists, researchers and medical experts that work tirelessly to identify new targets and develop innovative technologies that can improve patient outcomes.

2. Therapeutics segment: This segment consists of a range of RNA-based therapies that the company has developed for the treatment of viral infections. These therapies include products that are in clinical development for hepatitis B, HIV, influenza and other viral infections. Arbutus Biopharma Corp also offers preclinical therapies for oncology and other viral indications.

3. Partnerships segment: Arbutus Biopharma Corp has formed strategic partnerships and collaborations with leading pharmaceutical companies and research institutions around the world to develop and commercialize RNA-based therapies. The company has also licensed certain technologies and intellectual property rights that have helped to accelerate the development of its products.

Arbutus Biopharma Corp products and services include:

1. Lipid nanoparticle (LNP) technology: Arbutus Biopharma Corp holds an extensive patent portfolio in LNP technology. The company has developed a proprietary LNP platform that enables efficient delivery of RNA-based therapies to specific organs and tissues of the body. LNP technology has been used in several approved RNA-based therapies for the treatment of cancer and rare diseases.

2. C-Mer Side Effect Mitigation Technology: Arbutus Biopharma Corp has developed a proprietary technology for reducing the side effects of RNA-based therapies. This technology enhances the safety of RNA drugs by minimizing the risk of activation of the innate immune system which often leads to toxic responses.

3. HBV RNAi Portfolio: Arbutus Biopharma Corp has a portfolio of RNAi-based therapies that target the hepatitis B virus. These therapies have shown efficacy in various pre-clinical trials and are currently being tested in clinical trials.

Overall, Arbutus Biopharma Corp is committed to discovering, developing and providing innovative RNA-based therapies to combat infectious diseases. The company has excelled in several areas and continues to advance its RNA technologies to improve patient outcomes.
   

Arbutus Biopharma Tax Rate Companies within the Major Pharmaceutical Preparations Industry


Business Segments Q3
Revenues
(in millions $)
Q3
Income
(in millions $)
(Sep 30 2023)
%
(Profit Margin)
Total 4.66 -20.10 -

Growth rates by Segment Q3
Y/Y Revenue
%
(Sep 30 2023)
Q/Q Revenue
%
Q3
Y/Y Income
%
(Sep 30 2023)
Q/Q Income
%
Total -21.74 % 0.15 % - -

To get more information on Arbutus Biopharma's Total segment. Select each division with the arrow.


Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com